|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002475,
umls-concept:C0005740,
umls-concept:C0006826,
umls-concept:C0008838,
umls-concept:C0034656,
umls-concept:C0042682,
umls-concept:C0205221,
umls-concept:C0279933,
umls-concept:C0282461,
umls-concept:C0302592,
umls-concept:C1516985,
umls-concept:C1521808,
umls-concept:C2603343
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2001-8-27
|
|
pubmed:abstractText |
Three previous mitomycin-cisplatin-based chemotherapy trials conducted within the EORTC Gynecological Cancer Cooperative Group (GCCG) in patients with disseminated squamous-cell carcinoma of the uterine cervix (SCCUC) suggested that with such regimens a higher overall response rate and a higher complete response rate could be obtained compared to what might have been expected from cisplatin alone. In that respect the combination of bleomycin, vindesine (Eldesine), mitomycin C and cisplatin (BEMP) was the most promising. In the present study BEMP has been compared with the best single agent, cisplatin (P) in the expectation that improved response rates might translate into a better survival.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
967-74
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:11521804-Adult,
pubmed-meshheading:11521804-Aged,
pubmed-meshheading:11521804-Antibiotics, Antineoplastic,
pubmed-meshheading:11521804-Antineoplastic Agents,
pubmed-meshheading:11521804-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:11521804-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11521804-Bleomycin,
pubmed-meshheading:11521804-Carcinoma, Squamous Cell,
pubmed-meshheading:11521804-Cisplatin,
pubmed-meshheading:11521804-Drug Administration Schedule,
pubmed-meshheading:11521804-Europe,
pubmed-meshheading:11521804-Female,
pubmed-meshheading:11521804-Humans,
pubmed-meshheading:11521804-Middle Aged,
pubmed-meshheading:11521804-Mitomycin,
pubmed-meshheading:11521804-Prospective Studies,
pubmed-meshheading:11521804-Survival Analysis,
pubmed-meshheading:11521804-Treatment Outcome,
pubmed-meshheading:11521804-Uterine Neoplasms,
pubmed-meshheading:11521804-Vindesine
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study.
|
|
pubmed:affiliation |
Department of Oncology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
